Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
WALTHAM, Mass., March 21, 2017 -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat unmet medical needs of central nervous system (CNS) disorders, today announced the recent exercise of warrants held by certain institutional stockholders in connection with a private placement that took place in March 2015, as well as a purchase of common stock completed on the open market by the chairman of Minerva’s board of directors.
Since December 31, 2016, warrants with respect to a total of 1,621,073 shares have been exercised by such stockholders at an exercise price of $5.772 per share. As a result, the Company has received approximately $9.4 million in proceeds since December 31, 2016. The warrants issued in connection with the private placement expired on March 20, 2017.
Separately, 50,000 shares of Minerva common stock have been purchased by Marc Beer, chairman of the board of directors of Minerva. These purchases took place in multiple transactions at prices ranging from $7.65 to $8.45 and have been reflected in a Form 4 filing with the Securities and Exchange Commission on March 21, 2017.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases. Minerva’s proprietary compounds include: MIN-101, in clinical development for schizophrenia; MIN-117, in clinical development for major depressive disorder (MDD); MIN-202 (JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com.
Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376
